First author [ref. no.] | Study period | Patients n | Ext. Stage | Induction regime | High-dose regime | Radiotherapy | Survial |
Median months | 2-yr % | 5-yr % |
Brugger 42 | 1992–1994 | 18 | 0 | IFX 4 g·m−2 | IFX 4 g·m−2 | Chest: | | 78 | |
| | | | P 50 mg·m−2 | Carbo 250 mg·m−2 | 50 Gy | | | |
| | | | E 500 mg·m−2 | E 500 mg·m−2 | | | | |
| | | | EPI 50 mg·m−2 | EPI 50 mg·m−2 | PCI: | | | |
| | | | (Wk 1 & 3) | days 1–3 wk 7 | 30 Gy | | | |
| | | | | +PBSC+G-CSF | | | | |
Elias 43 | 1985–1994 | 36 | 0 | No standard | CTX 1875 mg·m−2 | Chest: | | 53 | 41 |
| | | | 4 series given | P 55 mg·m−2 | 50–56 Gy | | | |
| | | | in referring | BCNU 160 mg·m−2 | PCI: | | | |
| | | | dept. | days 1–3 | 30 Gy | | | |
| | | | | +marrow/PBSC (+G-CSF) | | | | |
Van de Velde 44 | 1993–1996 | 39 | 0 | IFX 3–4 g·m−2 days 1–3 | E 120–150 mg·m−2 days 1–3 | Chest: | 24.6 | 51 | 18 |
| | | | EPI 30–40 days 1–3 | Carbo AUC 5 days 1–2 | 2 Gy×5 | | | |
| | | | (Wk 3) | Wks 1, 3, 6 & 9 | | | | |
| | | | | IFX+EPI, wk 6 | | | | |
| | | | | E+Carbo, wk 9 | | | | |
| | | | | PBSC day 5 wk 3, 6, 9+G-CSF | | | | |
Leyvraz 45 | 1994–1997 | 69 | 39 | EPI 75 mg·m−2 days 1–2 | IFX 2.5 mg·m−2 | Chest: 37 pts | 13.5 | | |
| | | | | Carbo 300 mg·m−2 | No standard | LIM: 18 | 32 | 18 |
| | | | | E 300 mg·m−2 | PCI: 24 pts | EXT: 11 | 5 | 0 |
| | | | | Days 1–4 wk 3, 7, 11 | No standard | | | |
| | | | | PBS+G-CSF | | | | |
Bessho 46 | 1995–1997 | 11 | 5 | EXT: | IFX 3 g·m−2 days 1–4 | | 15, 17, 18 and >35 | | |
| | | | P 60 mg·m−2 days 1+8 | Carbo 400 mg·m−2 days 1, 3, 5 | | | | |
| | | | Irinp 50 mg·m−2 days 1+8 | E 500 mg·m−2 days 1, 3, 5 | | | | |
| | | | ×3–4 q. 3–4 wks | | | | | |
| | | | LIM: | | Chest: | >19, >21, >22, >23 | | |
| | | | P 50 mg·m−2 days 1+8 | | 1.5 Gy×30 | | | |
| | | | E 80 mg·m−2 days 1, 2, 8, 9 | | twice daily | | | |
| | | | Wk 1–3 | | | | | |